The Evoke ® System is the First SCS System to Demonstrate Cost-Dominance at Two Years Post-Implant MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical ...
ARTARMON, Australia, Jan. 21, 2020 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical") today announced that data from multiple studies evaluating the company's Evoke ® ECAP-Controlled, ...
The Evoke® SCS System is now covered by all major commercial payers and Medicare, providing broad patient access for this important therapy to over 200 million lives. 20 pain societies pledged their ...
MINNEAPOLIS, Aug. 4, 2023 /PRNewswire/ -- Saluda Medical, Inc. ("Saluda Medical"), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results